Description
Letrozole is a medication currently being studied in clinical trials for certain types of colorectal cancer. These trials are in Phase 1, which means they are primarily focused on determining the safety and appropriate dosage of letrozole, often in combination with other investigational drugs or standard treatments. The trials are looking at patients whose tumors have specific genetic changes, such as CCNE1 amplification or HER2 mutations/amplification. Letrozole is being investigated as a potential treatment option for these specific subgroups of colorectal cancer patients. The trials are still recruiting, meaning researchers are actively enrolling participants to evaluate the drug's effects.
Mechanism of Action
Letrozole is an aromatase inhibitor. Aromatase is an enzyme that converts androgens into estrogens. By inhibiting aromatase, letrozole lowers estrogen levels in the body. While primarily known for its use in breast cancer (where estrogen fuels tumor growth), its role in colorectal cancer is being investigated, particularly in tumors with specific genetic alterations like CCNE1 amplification or HER2 mutations/amplification, where hormonal pathways might play a role or where it might interact with other targeted therapies.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.